125033-36-5

Basic information

• Product Name: 3-(aminomethyl)-1-benzylpyrrolidin-3-ol
• Synonyms: 3-(aminomethyl)-1-benzylpyrrolidin-3-ol
• CAS NO: 125033-36-5
• Molecular Weight: 206.288
• Mol File: 125033-36-5.mol
• Article Data: 6

Chemical Properties

• CAS DataBase Reference: 3-(aminomethyl)-1-benzylpyrrolidin-3-ol(CAS DataBase Reference)
• NIST Chemistry Reference: 3-(aminomethyl)-1-benzylpyrrolidin-3-ol(125033-36-5)
• EPA Substance Registry System: 3-(aminomethyl)-1-benzylpyrrolidin-3-ol(125033-36-5)

Safety Data

• Hazardous Substances Data: 125033-36-5(Hazardous Substances Data)

Upstream product

• 97266-84-7 5-benzyl-1-oxa-5-azaspiro[2.4]heptane 
• 775-16-6 N-benzyl-3-pyrrolidinone 

Downstream Products

• 125033-59-2 3-tert-Butoxycarbonylaminomethyl-3-hydroxy-pyrrolidine 
• 637039-01-1 tert-butyl 6-oxa-2,9-diazaspiro[4.5]decane-9-carboxylate 
• 944774-98-5 2-benzyl-6-oxa-2,9-diazaspiro[4.5]decan-8-one 

Relevant articles and documents

5-MEMBERED HETEROARYLAMINOSULFONAMIDES FOR TREATING CONDITIONS MEDIATED BY DEFICIENT CFTR ACTIVITY

The invention relates to heteroaryl compounds, pharmaceutically acceptable salts thereof, and pharmaceutical preparations thereof. Also described herein are compositions and the use of such compounds in methods of treating diseases and conditions mediated by deficient CFTR activity, in particular cystic fibrosis.

N-(HETERO)ARYL-SUBSTITUTED HETEROYCLIC DERIVATIVES USEFUL FOR THE TREATMENT OF DISEASES OR CONDITIONS RELATED TO THE CENTRAL NERVOUS SYSTEM

The present invention provides compounds of formula (I): compositions comprising such compounds; the use of such compounds in therapy (for example in the treatment or prevention of a disease, disorder or condition ameliorated by inhibition of a dopamine transporter); and methods of treating patients with such compounds; wherein R1, R2, R3, R4, R9a, R9b, R9c, R9d, R9e, R9f, m, n, A, L and B are as defined herein.

2-[BIS(4-FLUOROPHENYL)METHYL]-2,7-DIAZASPIRO[4.5]DECAN-10-ONE DERIVATIVES AND RELATED COMPOUNDS AS INHIBITORS OF THE HUMAN DOPAMINE-ACTIVE-TRANSPORTER (DAT) PROTEIN FOR THE TREATMENT OF E.G. ATTENTION DEFICIT DISORDER (ADD)

The present invention provides compounds of formula (I) and in particular 2-[bis(4-fluorophenyl)methyl]-2,7- diazaspiro[4.5]decan-10-one derivatives and related compounds as inhibitors of human dopamine-active-transporter (DAT) protein for the treatment of sexual dysfunction, affective disorders, anxiety, depression, chronic fatigue, Tourette syndrome, Angelman syndrome, attention deficit disorder (ADD), attention deficit hyperactivity disorder (ADHD), obesity, pain, obsessive-compulsive disorder, movement disorders, CNS disorders, sleep disorders, narcolepsy, conduct disorder, substance abuse (including smoking cessation), eating disorders, and impulse control disorders.